A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 in Active Plaque Psoriasis

Trial Profile

A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 in Active Plaque Psoriasis

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2015

At a glance

  • Drugs Dalazatide (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Kineta
  • Most Recent Events

    • 09 Jun 2015 As per a Kineta media release, results from this trial will be presented at the Biotechnology Industry Organization (BIO) Annual Meeting in Philadelphia.
    • 05 May 2015 Results were published in a Kineta media release.
    • 05 May 2015 According to a Kineta media release, results from biomarker analysis of this study are expected to be available in the second quarter of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top